Recruiting
Phase 2

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Sponsor:

Criterium, Inc.

Code:

NCT05458674

Conditions

Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tucatinib

Eribulin

Trastuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information